REG - Yourgene Health PLC - Amendment to Share Options

Yourgene HealthAnnouncement

12/08/2019 07:05

RNS Number : 6113I
Yourgene Health PLC
12 August 2019
 


 
Yourgene Health plc
("Yourgene" or the "Company")
 
Amendment to Share Options
 
Manchester, UK - 12 August 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces an amendment to existing share options held by certain Directors of the Company.
 
The existing share options below (issued 19 March 2014) have had their performance conditions modified so as to be aligned with other senior incentives:
 




Name


Existing options subject to amendment


Total number of options held




Adam Reynolds


591,666


591,666




Nick Mustoe


591,666


591,666




 
The exercise price of these options has not been changed and remains at 10 pence.
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
 
 
 




For more information, please contact:


 




Yourgene Health plc


Tel: +44 (0)161 667 1053




Lyn Rees, Chief Executive Officer


 




Barry Hextall, Chief Financial Officer


 




Joanne Cross, Head of Marketing            


 




investors@yourgene-health.com


 




 


 




Cairn Financial Advisers LLP (Nomad)


Tel: +44 (0)20 7213 0880




Liam Murray / James Caithie / Ludovico Lazzaretti


 




 


 




Stifel Nicolaus Europe Limited (Corporate Broker)


Tel: +44 (0)20 7710 7600




Nicholas Moore / Matthew Blawat / Ben Maddison


 




                                                                                                   


 




Walbrook PR Ltd (Media and Investor Relations)


Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com




Paul McManus / Lianne Cawthorne / Anna Dunphy


Mob: 07980 541 893 / 07584 391 303 /




 


07876 741 001  



 
 
 
 
 



 
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 
 
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
 
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
 
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHZKLFBKVFBBBF